History of aspirin other studies from the 1960s to the 1980s established aspirin's efficacy as an anti-clotting agent that reduces the risk of clotting diseases. Aspirin sales revived considerably in the last decades of the twentieth century, and remain strong in the twenty-first with widespread use as a preventive treatment for heart attacks and strokes. Medicines derived from willow trees and other salicylate-rich plants have been part of pharmacopoeias at least dating back to ancient Sumer. The Ebers Papyrus, an Egyptian medical text from ca. 1543 BCE, mentions use of willow and myrtle (another salicylate-rich plant) to treat fever and pain. Willow bark
History of aspirin from Spirsäure, and added -in as a typical drug name ending to make it easy to say. In the final round of naming proposals that circulated through Bayer, it came down to "Aspirin" and "Euspirin"; "Aspirin", they feared, might remind customers of aspiration, but Arthur Eichengrün argued that "Eu"- (meaning "good") was inappropriate because it usually indicated an improvement over an earlier version of a similar drug. Since the substance itself was already known, Bayer intended to use the new name to establish their drug as something new; in January 1899 they settled on "Aspirin". Under Carl Duisberg's leadership, Bayer